These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25495808)

  • 1. A vascular physician's view of venous thromboembolism and apixaban.
    Cohen A; Wu WH
    Future Cardiol; 2014 Nov; 10(6):679-81. PubMed ID: 25495808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interview with Alexander Cohen.
    Cohen AA
    Future Cardiol; 2017 May; 13(3):207-209. PubMed ID: 28569545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy].
    Oka S; Takeuchi S; Shiragami H; Hamahata K; Nohgawa M
    Rinsho Ketsueki; 2017; 58(1):37-41. PubMed ID: 28190864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Would apixaban be a good option for extended anticoagulation in venous thromboembolism?
    Wu MA; Cernuschi G
    Intern Emerg Med; 2014 Feb; 9(1):99-100. PubMed ID: 23857037
    [No Abstract]   [Full Text] [Related]  

  • 5. Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
    Monreal M
    Thromb Haemost; 2018 Nov; 118(11):1850-1851. PubMed ID: 30332697
    [No Abstract]   [Full Text] [Related]  

  • 6. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
    Kimpton M; Wells PS; Carrier M
    Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.
    Reynolds ML; Nachman PH; Mooberry MJ; Crona DJ; Derebail VK
    J Nephrol; 2019 Aug; 32(4):669-672. PubMed ID: 30421320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apixaban in the treatment of venous thrombosis associated with permanent pacemaker implantation].
    Carrizo S; Figueroa JA; Vivero A
    Medicina (B Aires); 2015; 75(6):410-2. PubMed ID: 26707667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban: an oral direct factor-xa inhibitor.
    Jiménez D; Yusen RD; Ramacciotti E
    Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
    Lee S; White CM
    Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
    [No Abstract]   [Full Text] [Related]  

  • 13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
    Martin MT; Nutescu EA
    Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Li XM; Sun SG; Zhang WD
    Chin Med J (Engl); 2012 Jul; 125(13):2339-45. PubMed ID: 22882859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
    Morris TA
    Clin Chest Med; 2010 Dec; 31(4):707-18. PubMed ID: 21047577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New anticoagulants in the treatment of venous thromboembolism].
    Bura-Rivière A
    Rev Prat; 2013 Sep; 63(7):980-4. PubMed ID: 24167902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of oral factor Xa inhibitors.
    Hylek EM
    N Engl J Med; 2010 Dec; 363(26):2559-61. PubMed ID: 21175319
    [No Abstract]   [Full Text] [Related]  

  • 20. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.